Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
- Author
- MERRILL, Joan T1 ; WALLACE, Daniel J2 ; OLSEN, Nancy10 9 ; RICHMAN, Laura5 ; LE, Chenxiong5 ; JALLAL, Bahija5 ; WHITE, Barbara11 5 ; PETRI, Michelle3 ; KIROU, Kyriakos A4 ; YIHONG YAO5 ; WHITE, Wendy I5 ; ROBBIE, Gabriel5 ; LEVIN, Robert6 ; BERNEY, Seth M7 ; CHINDALORE, Vishala8
[1] Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
[2] Wallace Rheumatic Study Center, Los Angeles, California, United States
[3] Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
[4] Mary Kirkland Center for Lupus Care, Hospital for Special Surgery, New York, NY, United States
[5] Medlmmune, LLC, Gaithersburg, Maryland, United States
[6] Clinical Research of West Florida Inc, Clearwater, Florida, United States
[7] Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
[8] Pinnacle Research Group, LLC, Anniston, Alabama, United States
[9] Department of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
[10] Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
[11] UCB Biosciences, Raleigh, North Carolina, United States
Lupus Interferon Skin Activity (LISA) Study Investigators - Source
Annals of the rheumatic diseases. 2011, Vol 70, Num 11, pp 1905-1913, 9 p ; ref : 54 ref
- CODEN
- ARDIAO
- ISSN
- 0003-4967
- Scientific domain
- Rheumatology
- Publisher
- BMJ Publishing Group, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticorps monoclonal Essai clinique phase I Etude double insu Homme Interféron alpha Lupus érythémateux disséminé Rhumatologie Toxicité Immunopathologie Maladie autoimmune Maladie de système Pathologie de la peau Pathologie du tissu conjonctif
- Keyword (en)
- Monoclonal antibody Phase I trial Double blind study Human Alpha interferon Systemic lupus erythematosus Rheumatology Toxicity Immunopathology Autoimmune disease Systemic disease Skin disease Connective tissue disease
- Keyword (es)
- Anticuerpo monoclonal Ensayo clínico fase I Estudio doble ciego Hombre Interferón alfa Lupus eritematoso sistémico Reumatología Toxicidad Inmunopatología Enfermedad autoinmune Enfermedad sistémica Piel patología Tejido conjuntivo patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B07 Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B15 Diseases of the osteoarticular system
- Discipline
- Osteoarticular pathology Sarcoidosis. Granulomatosis of undetermined origin. Connective tissue diseases. Vasculitides
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24603570
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1136/ard.2010.144485 
https://dx.doi.org/10.1136/ard.2010.144485
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.144485\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1905\";s:8:\"\u0000*\u0000epage\";s:4:\"1913\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MERRILL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joan T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"WALLACE, Daniel J\";i:1;s:12:\"OLSEN, Nancy\";i:2;s:14:\"RICHMAN, Laura\";i:3;s:13:\"LE, Chenxiong\";i:4;s:14:\"JALLAL, Bahija\";i:5;s:14:\"WHITE, Barbara\";i:6;s:15:\"PETRI, Michelle\";i:7;s:17:\"KIROU, Kyriakos A\";i:8;s:10:\"YIHONG YAO\";i:9;s:14:\"WHITE, Wendy I\";i:10;s:15:\"ROBBIE, Gabriel\";i:11;s:13:\"LEVIN, Robert\";i:12;s:14:\"BERNEY, Seth M\";i:13;s:19:\"CHINDALORE, Vishala\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.144485\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1905\";s:8:\"\u0000*\u0000epage\";s:4:\"1913\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MERRILL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joan T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"WALLACE, Daniel J\";i:1;s:12:\"OLSEN, Nancy\";i:2;s:14:\"RICHMAN, Laura\";i:3;s:13:\"LE, Chenxiong\";i:4;s:14:\"JALLAL, Bahija\";i:5;s:14:\"WHITE, Barbara\";i:6;s:15:\"PETRI, Michelle\";i:7;s:17:\"KIROU, Kyriakos A\";i:8;s:10:\"YIHONG YAO\";i:9;s:14:\"WHITE, Wendy I\";i:10;s:15:\"ROBBIE, Gabriel\";i:11;s:13:\"LEVIN, Robert\";i:12;s:14:\"BERNEY, Seth M\";i:13;s:19:\"CHINDALORE, Vishala\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.144485\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.144485\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1905\";s:8:\"\u0000*\u0000epage\";s:4:\"1913\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MERRILL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joan T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"WALLACE, Daniel J\";i:1;s:12:\"OLSEN, Nancy\";i:2;s:14:\"RICHMAN, Laura\";i:3;s:13:\"LE, Chenxiong\";i:4;s:14:\"JALLAL, Bahija\";i:5;s:14:\"WHITE, Barbara\";i:6;s:15:\"PETRI, Michelle\";i:7;s:17:\"KIROU, Kyriakos A\";i:8;s:10:\"YIHONG YAO\";i:9;s:14:\"WHITE, Wendy I\";i:10;s:15:\"ROBBIE, Gabriel\";i:11;s:13:\"LEVIN, Robert\";i:12;s:14:\"BERNEY, Seth M\";i:13;s:19:\"CHINDALORE, Vishala\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.144485\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1905\";s:8:\"\u0000*\u0000epage\";s:4:\"1913\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MERRILL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joan T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"WALLACE, Daniel J\";i:1;s:12:\"OLSEN, Nancy\";i:2;s:14:\"RICHMAN, Laura\";i:3;s:13:\"LE, Chenxiong\";i:4;s:14:\"JALLAL, Bahija\";i:5;s:14:\"WHITE, Barbara\";i:6;s:15:\"PETRI, Michelle\";i:7;s:17:\"KIROU, Kyriakos A\";i:8;s:10:\"YIHONG YAO\";i:9;s:14:\"WHITE, Wendy I\";i:10;s:15:\"ROBBIE, Gabriel\";i:11;s:13:\"LEVIN, Robert\";i:12;s:14:\"BERNEY, Seth M\";i:13;s:19:\"CHINDALORE, Vishala\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1136\/ard.2010.144485\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1905\";s:8:\"\u0000*\u0000epage\";s:4:\"1913\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MERRILL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joan T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"WALLACE, Daniel J\";i:1;s:12:\"OLSEN, Nancy\";i:2;s:14:\"RICHMAN, Laura\";i:3;s:13:\"LE, Chenxiong\";i:4;s:14:\"JALLAL, Bahija\";i:5;s:14:\"WHITE, Barbara\";i:6;s:15:\"PETRI, Michelle\";i:7;s:17:\"KIROU, Kyriakos A\";i:8;s:10:\"YIHONG YAO\";i:9;s:14:\"WHITE, Wendy I\";i:10;s:15:\"ROBBIE, Gabriel\";i:11;s:13:\"LEVIN, Robert\";i:12;s:14:\"BERNEY, Seth M\";i:13;s:19:\"CHINDALORE, Vishala\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:193:\"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:20:\"BMJ Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
